GlaxoSmithKline Plc in Consumer Health

November 2021

GlaxoSmithKline (GSK) continues to be the market leader in consumer health. While its strength remains in analgesics, digestive remedies, and vitamins and dietary supplements, the lack of a strong allergy remedy portfolio hurt the recovery of cough, cold and allergy remedies in 2021. The business witnessed its fastest growth in 2021 in Middle East and Africa, followed by Asia Pacific. Supported by its powerbrands, the business will be spun off as a separate consumer health entity in 2022.

USD 570
Request More Information


Files are delivered directly into your account soon after payment is received and any tax certification is verified (where applicable).

This report comes in PPT.


Euromonitor International's report on GlaxoSmithKline Plc delivers a detailed strategic analysis of the company's business, examining its performance in the Consumer Health market and the global economy. Company and market share data provide a detailed look at the financial position of GlaxoSmithKline Plc, while in-depth qualitative analysis will help you understand the brand strategy and growth prospects of GlaxoSmithKline Plc.

This report examines:

  • Company share by region and sector
  • Brand portfolio
  • New product developments
  • Marketing and distribution strategies

A detailed SWPT analysis of GlaxoSmithKline Plc provides strategic intelligence on:

  • Strengths and weaknesses
  • Category and country opportunities for growth
  • Challenges and threats from current competition and future prospects
  • Global and regional market positions

Research you can trust:

Euromonitor International's company profile reports are written by our Consumer Health research team, a dedicated group of analysts that knows the industry inside and out. Buy this report to inform your planning, strategy, marketing, sales and competitor intelligence functions.

Executive summary
GlaxoSmithKline remains the market leader in 2021
GlaxoSmithKline’s global footprint
Company overview
Strength of past mergers supports spin-off of consumer health business
GSK details commitments to combatting climate change
Future growth in the US is crucial
Investment in dietary supplements will cement future competitiveness
GSK’s global presence is a key competitive advantage
While leading globally, GSK has few leading brands at the country level
Middle East delivers consistently high growth
GSK: Western Europe is the only region where topical analgesics lead
Panadol and Voltaren have better prospects than Advil
Centrum is singlehandedly responsible for GSK’s success in vitamins
Caltrate and Emergen-C offer a more balanced approach
Non-herbal/traditional dietary supplements lead for GSK
Majority growth in the future to come from US and China
Consumers’ quest for immunity and other benefits will bolster growth
COVID-19’s impact pushes CCAs down to GSK’s third largest category
Lack of a strong allergy remedy brand further slows recovery
North America shoulders digestive remedies sales for GSK
Indigestion and heartburn remedies dominate the digestive portfolio
China is an exception in dermatologicals for GSK
COVID-19 brings sleep aids in focus
Key findings
Projected company s ales: FAQs (1)
Projected company s ales: FAQs (2)

Consumer Health

It is the aggregation of OTC, Vitamins and Dietary Supplements (VDS), Sports Nutrition, and Weight Management and Wellbeing

See All of Our Definitions

Why buy this report:

Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions


If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extraction Free!